Generic Name and Formulations:
Acetaminophen 10mg/mL; soln for IV infusion; preservative-free.
Indications for OFIRMEV:
Management of mild-to-moderate pain or moderate-to-severe pain with adjunctive opioid analgesics. Fever.
Ensure total amount of acetaminophen from all routes and all sources does not exceed max recommended dose. Give by IV infusion over 15 mins. <50kg: 15mg/kg every 6hrs (or 12.5mg/kg every 4hrs); max single dose: 15mg/kg (up to 750mg), max daily dose: 75mg/kg/24hrs (up to 3750mg). ≥50kg: 1000mg every 6hrs (or 650mg every 4hrs); max single dose: 1000mg, max daily dose: 4000mg/24hrs. Minimum dosing interval: 4hrs.
Ensure total amount of acetaminophen from all routes and all sources does not exceed max recommended dose. Give by IV infusion over 15 mins; place small volume doses (up to 60mL) in syringe and administer using syringe pump. Fever only: (Neonates 0–28days): 12.5mg/kg every 6hrs; max daily dose: 50mg/kg/24hrs; (Infants 29days–2yrs): 15mg/kg every 6hrs; max daily dose: 60mg/kg/24hrs. Minimum dosing interval: 6hrs. Fever/pain: (<2yrs): not established (for pain); (≥2yrs): 15mg/kg every 6hrs (or 12.5mg/kg every 4hrs); max single dose: 15mg/kg (up to 750mg), max daily dose: 75mg/kg/24hrs (up to 3750mg). Minimum dosing interval: 4hrs.
Severe hepatic impairment. Severe active liver disease.
Risk of medication errors. Hepatotoxicity.
Ensure correct prescribing, preparing, and administering to avoid dosing errors. Risk of acute liver failure (may result in liver transplant or death) associated with the use of doses higher than recommended or involving >1 acetaminophen-containing product. Hepatic impairment. Active hepatic disease. Alcoholism. Chronic malnutrition. Severe hypovolemia. Severe renal impairment (CrCl ≤30mL/min). Pregnancy. Nursing mothers.
Caution with CYP2E1 inhibitors or inducers (eg, alcohol). Doses of 4000mg/day may increase INR, monitor warfarin frequently.
Nausea, vomiting, headache, insomnia; also children: constipation, pruritus; hepatotoxicity (with high doses), hypersensitivity (discontinue if occurs); rare: serious skin reactions (eg, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis).
Single-dose vials or bags (100mL)—24
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- Two Programs, One Goal: Meeting the Challenges of Oncology Navigation
- Navigating Patients with Hematologic Malignancies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|